Clinical trials: Multiple Myeloma Bone Lesions, open to volunteers
Vertebral Fracture, Multiple Myeloma
Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.
Patients with newly diagnosed or known multiple myeloma with newly diagnosed vertebral lesion(s) will be invited to participate in a cross-sectoral randomized controlled trial.
- Trial name
- NCT04533217
- Testing
- Vertebroplasty
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Spine Centre of Southern Denmark
Multiple Myeloma Bone Disease
"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma
Recent work has confirmed the diagnostic performance of pseudo-CT sequences for detecting osteolytic lesions. Their integration into whole body MRI (WB MRI) could transform the diagnostic approach to MM, by allowing a combined…
- Trial name
- MM-ZTE-II (NCT06988020)
- Testing
- MRI
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Multiple Myeloma Bone Lesions
Exercise Therapy for Multiple Myeloma Patients
Physical exercise is an important supportive therapy for cancer patients, as it improves quality of life in general and might mitigate the side effects of drug treatment.
- Trial name
- SAPPHIRE-MM (NCT07388147)
- Testing
- Orthopedic consultation and rehabilitation by excercise therapy
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- University Hospital Heidelberg
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade
- Trial name
- NCT02269592
- Where
- 7 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Dana-Farber Cancer Institute